What is Union Agener?
Headquartered in Augusta, Georgia, Union Agener operates as a specialized biotechnology entity dedicated to the advancement of animal health products. The company is best known for its production of Posilac, a recombinant bovine somatotropin designed to optimize milk production cycles in dairy cattle. By leveraging sophisticated biological engineering, Union Agener provides dairy farmers and large-scale agricultural enterprises with the tools necessary to enhance yield metrics while maintaining rigorous standards of sustainability. The firm serves as a critical link in the global dairy supply chain, bridging the gap between laboratory innovation and practical farm-level application.
How much funding has Union Agener raised?
Union Agener has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Union Agener
PPP
Public-Private Partnership
What's next for Union Agener?
With the recent influx of capital, Union Agener is expected to transition into a phase of aggressive operational expansion and market penetration. The strategic focus will likely shift toward optimizing the distribution channels for its core product line and exploring potential adjacencies in the broader veterinary biotechnology market. As the agricultural sector faces increasing pressure to improve output efficiency, Union Agener's ability to scale its production capabilities will be paramount. Investors and industry stakeholders will be monitoring the company's progress in integrating these new resources to drive long-term value and maintain its competitive edge in the global animal health arena.
See full Union Agener company page
